Data / Drug companies / Advagen Pharma Ltd
Advagen Pharma Ltd: 218 products in the FDA NDC directory, labeler code 72888
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Advagen Pharma Ltd (labeler code 72888) lists 218 products in the FDA National Drug Code Directory, covering 75 finished drugs by generic name. By type: 212 prescription drugs, 6 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 28, 2026.
The request: Watch Advagen Pharma Ltd (FDA labeler code 72888): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72888
- Products in commercial distribution
- 218
- Packages
- 522
- Finished drugs by generic name
- 75
- Prescription products
- 212
- Over the counter products
- 6
- Controlled substance products
- Schedule III 4, Schedule IV 13, Schedule V 3
- Flagged as original packager
- 193 of 193 products that carry the flag
- Started marketing in the last 12 months
- 19
- Earliest marketing start
- November 16, 2000
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 211 | 96.8% |
| Authorized generics (NDA) | 6 | 2.8% |
| Over the counter monograph drugs | 1 | 0.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 212 | 97.2% |
| Over the counter drugs | 6 | 2.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 87 | 39.9% |
| Tablet, film coated | 36 | 16.5% |
| Solution | 19 | 8.7% |
| Tablet, extended release | 15 | 6.9% |
| Capsule | 14 | 6.4% |
| Tablet, coated | 7 | 3.2% |
| Tablet, film coated, extended release | 6 | 2.8% |
| Tablet, delayed release | 6 | 2.8% |
| Tablet, orally disintegrating | 6 | 2.8% |
| Capsule, extended release | 4 | 1.8% |
| Suspension | 4 | 1.8% |
| Spray | 3 | 1.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Triamterene | 72888-505 | Capsule | Generic drugs (ANDA) | October 28, 2026 |
| Triamterene | 72888-504 | Capsule | Generic drugs (ANDA) | October 28, 2026 |
| Hydrochlorothiazide | 72888-491 | Solution | Generic drugs (ANDA) | October 7, 2026 |
| Pentoxifylline | 72888-268 | Tablet | Authorized generics (NDA) | October 1, 2026 |
| Diclofenac Potassium | 72888-203 | Tablet, coated | Generic drugs (ANDA) | September 18, 2026 |
| Hydroxyzine Hydrochloride | 72888-218 | Solution | Generic drugs (ANDA) | September 11, 2026 |
| Spironolactone and hydrochlorothiazide | 72888-040 | Tablet | Generic drugs (ANDA) | September 10, 2026 |
| Dicyclomine hydrochloride | 72888-105 | Capsule | Generic drugs (ANDA) | July 17, 2026 |
| Promethazine Hydrochloride and Dextromethorphan Hydrobromide | 72888-038 | Solution | Generic drugs (ANDA) | June 23, 2026 |
| Clonazepam | 72888-497 | Tablet | Generic drugs (ANDA) | June 12, 2026 |
| Clonazepam | 72888-137 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 21, 2026 |
| Clonazepam | 72888-136 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 21, 2026 |
| Clonazepam | 72888-135 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 21, 2026 |
| Clonazepam | 72888-134 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 21, 2026 |
| Clonazepam | 72888-133 | Tablet, orally disintegrating | Generic drugs (ANDA) | May 21, 2026 |
| Atomoxetine hydrochloride | 72888-456 | Solution | Authorized generics (NDA) | March 20, 2026 |
| Childrens ibuprofen | 72888-479 | Suspension | Generic drugs (ANDA) | March 5, 2026 |
| Cetirizine hydrochloride | 72888-480 | Solution | Generic drugs (ANDA) | February 25, 2026 |
| Buprenorphine hydrochloride | 72888-510 | Tablet | Generic drugs (ANDA) | February 1, 2026 |
| Dexamethasone | 72888-241 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Dexamethasone | 72888-240 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Dexamethasone | 72888-239 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Dexamethasone | 72888-238 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Dexamethasone | 72888-237 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
| Dexamethasone | 72888-236 | Tablet | Generic drugs (ANDA) | October 15, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.